WO2004034967A3 - 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety - Google Patents

2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety Download PDF

Info

Publication number
WO2004034967A3
WO2004034967A3 PCT/US2003/025134 US0325134W WO2004034967A3 WO 2004034967 A3 WO2004034967 A3 WO 2004034967A3 US 0325134 W US0325134 W US 0325134W WO 2004034967 A3 WO2004034967 A3 WO 2004034967A3
Authority
WO
WIPO (PCT)
Prior art keywords
anxiety
depression
subject
provides
compound
Prior art date
Application number
PCT/US2003/025134
Other languages
French (fr)
Other versions
WO2004034967A2 (en
Inventor
Mathivanan Packiarajan
Original Assignee
Synaptic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharma Corp filed Critical Synaptic Pharma Corp
Priority to AU2003298547A priority Critical patent/AU2003298547A1/en
Publication of WO2004034967A2 publication Critical patent/WO2004034967A2/en
Publication of WO2004034967A3 publication Critical patent/WO2004034967A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

This invention is directed to pyrimidine derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.
PCT/US2003/025134 2002-08-07 2003-08-07 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety WO2004034967A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298547A AU2003298547A1 (en) 2002-08-07 2003-08-07 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21525802A 2002-08-07 2002-08-07
US10/215,258 2002-08-07

Publications (2)

Publication Number Publication Date
WO2004034967A2 WO2004034967A2 (en) 2004-04-29
WO2004034967A3 true WO2004034967A3 (en) 2004-07-15

Family

ID=32106342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025134 WO2004034967A2 (en) 2002-08-07 2003-08-07 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Country Status (3)

Country Link
AU (1) AU2003298547A1 (en)
TW (1) TW200412968A (en)
WO (1) WO2004034967A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Also Published As

Publication number Publication date
AU2003298547A8 (en) 2004-05-04
WO2004034967A2 (en) 2004-04-29
AU2003298547A1 (en) 2004-05-04
TW200412968A (en) 2004-08-01

Similar Documents

Publication Publication Date Title
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2002053177A3 (en) Agents and methods for treating pain
HK1082728A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
MXPA02001306A (en) Pharmaceutical compositions for the treatment of cns and other discorders.
MXPA03007513A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists.
IL165906A0 (en) As mch1 antagonists and uses thereof
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
MXPA04005209A (en) ADENOSINE A ??2a? RECEPTOR ANTAGONISTS.
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2004064764A3 (en) Substituted alkyl amido piperidines
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
UA85575C2 (en) 4-aryl piperidines
YU60803A (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2004014307A3 (en) Gal3 antagonists for the treatment of neuropathic pain
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2006041636A3 (en) Amino substituted aryloxybenzylpiperidine derivatives
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
WO2000076457A3 (en) Il-8 receptor antagonists
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP